Ramsay R A, Ban T A, Lehmann H E, Saxena B M, Bennett J
Can Med Assoc J. 1970 May 9;102(9):939-42.
A placebo-controlled, comparative clinical study was conducted to test the hypothesis that nicotinic acid as an adjuvant medication has a beneficial therapeutic effect over and above the effect which can be achieved by the administration of phenothiazine drugs alone, over a six-month period, in newly (recently) admitted schizophrenic patients.The most important single finding was that no statistically significant therapeutic difference was seen between the active treatment and the placebo groups; i.e., the addition of nicotinic acid or nicotinamide to the regular phenothiazine treatment regimen did not have any measurable therapeutic effect in this sample of patients. It was shown that patients in the placebo group received a lower total daily amount of phenothiazine drugs than those on either of the active substances. Furthermore, it was noted that the addition of the active substances did not reduce the number of days of hospitalization.
一项安慰剂对照的比较性临床研究开展，旨在检验以下假设：在为期六个月的时间里，对于新入院（近期入院）的精神分裂症患者，烟酸作为辅助药物除了单独使用吩噻嗪类药物所能达到的效果外，还具有有益的治疗作用。最重要的单一发现是，在活性治疗组和安慰剂组之间未观察到统计学上显著的治疗差异；也就是说，在常规吩噻嗪治疗方案中添加烟酸或烟酰胺对该样本患者没有任何可测量的治疗效果。结果显示，安慰剂组患者每日接受的吩噻嗪类药物总量低于使用任何一种活性物质的患者。此外，还注意到添加活性物质并未减少住院天数。
